Charles River Laboratories International, Inc. (CRL)

Market Cap	10.67B
Revenue (ttm)	4.02B -0.9%
Net Income	-83.48M
EPS	-1.67
Shares Out	49.22M
PE Ratio	n/a
Forward PE	20.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	444,601
Open	218.45
Previous Close	219.53
Day's Range	214.48 - 219.37
52-Week Range	91.86 - 228.88
Beta	1.62
Analysts	Buy
Price Target	205.27 (-5.35%)
Earnings Date	Feb 18, 2026

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 20,100
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Financial Performance

In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.

Analyst Summary

According to 12 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $205.27, which is a decrease of -5.35% from the latest price.

Price Target

$205.27

(-5.35% downside)

Analyst Consensus: Buy